Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing the oral CETP inhibitor obicetrapib for LDL-C lowering in patients at risk of cardiovascular disease. Through these regulatory documents, investors can review how NewAmsterdam reports its clinical progress, financial position and corporate actions.
Current reports on Form 8-K are used by NewAmsterdam to disclose material events such as quarterly financial results, corporate updates and the publication of investor presentations. For example, the company has filed an 8-K to furnish a press release announcing financial results for a recent quarter and to make an updated corporate investor presentation available as an exhibit. Such filings can give context on research and development spending, cash and marketable securities, and the status of key clinical and regulatory milestones.
NewAmsterdam also uses SEC filings to document equity-related matters, including inducement share option grants made under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). These disclosures outline the size of option grants, vesting schedules and exercise prices for new hires, providing insight into compensation practices and share-based incentives.
On Stock Titan, NewAmsterdam’s SEC filings are updated as they are made available from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections and clarify terminology. Users can quickly locate quarterly and annual reports when filed, review 8-Ks describing clinical and regulatory developments, and examine exhibits such as press releases and corporate presentations. This makes it easier to understand how NewAmsterdam communicates the evolution of its obicetrapib program, its collaboration and licensing arrangements, and other corporate information in its official regulatory record.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported open-market sales of a total of 44,619 Ordinary Shares on March 11, 2026. He sold 44,173 shares at a weighted average price of $30.41 per share and 446 shares at a weighted average price of $31.23 per share. After these sales, he directly owns 10,360 Ordinary Shares. The prices reflect multiple trades in ranges from $30.11 to $31.31 per share.
NewAmsterdam Pharma Company N.V. resale filing shows planned and recent transfers of Ordinary Shares. The filing lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. It also records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026 for $828,849.41.
This Form 144 excerpt documents resale activity by a trust and a warrant-related issuance; cash‑flow treatment for proceeds beyond the warrant exercise is not detailed in the excerpt.
NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.
Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.
NewAmsterdam Pharma Company N.V. furnished an updated investor presentation that highlights the development and commercialization plans for its CETP inhibitor obicetrapib.
The company describes obicetrapib as a once-daily oral therapy that produced LDL-C reductions of about 35–40% as monotherapy and roughly 50–60% when combined with ezetimibe across multiple Phase 2 and Phase 3 trials, with additional ~45% Lp(a) lowering versus placebo in pooled analyses. Exploratory analyses from the Phase 3 BROADWAY trial showed an observed 21% reduction in major adverse cardiovascular events at one year versus placebo, with pooled BROADWAY and BROOKLYN data also favoring obicetrapib, while noting these studies were not powered for outcomes.
The presentation outlines a potential global peak sales opportunity of more than $8 billion for cardiometabolic use, citing over 30 million U.S. patients on lipid-lowering drugs who are not at LDL-C goal. It also reports cash, cash equivalents and marketable securities of approximately $729 million at year-end 2025, intended to support a prospective U.S. launch if approved. Additional data show a 2.84% treatment benefit on p‑tau217 progression overall and a 20.5% benefit in ApoE4 homozygotes over 12 months, along with favorable changes in other Alzheimer’s biomarkers. The company emphasizes intellectual property protection, including composition-of-matter coverage extending into 2043, and a broad late-stage clinical program, including the PREVAIL cardiovascular outcomes trial and multiple Phase 3 and Phase 2 studies.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported a multi-day option exercise-and-sell transaction from February 24 through February 26, 2026, under a Rule 10b5-1 trading plan. He exercised options for 306,293 ordinary shares at EUR 1.16392 per share and sold 306,293 shares at prices ranging from $33.63 to $36.68 per share.
The filing also reports a February 26 transfer of 285,715 ordinary shares to a grantor retained annuity trust (GRAT). Following the transactions, Davidson held 174,144 ordinary shares directly and 285,715 shares indirectly through the GRAT, with 682,974 options remaining under the reported grant.